Pneumonia – Diagnosis and Treatment

Report Overview

In 2014, US healthcare spending exceeded $3.0 trillion with nearly 1/3 spent on hospitalizations. Informed by real-world data from an Electronic Health Record (EHR) database of clinical and administrative records spanning 273 million encounters for 60 million patients in 600+ hospitals across the US, Boston Strategic Partners (BSP) Real World data report, Hospital-Treated Pneumonia, estimates 30% of all hospital discharges involve treatment of infectious organisms. Pneumonia is responsible for an estimated 12% of all hospital stays. At an average cost of $15,500 per occurrence, we estimate that hospitalizations for severe infections account for around $212 billion in annual spending or 7% of total healthcare expenditure. In this report, we conduct an in-depth analysis of pneumonia patient characteristics, medication management, costs, and laboratory testing.

Hospital-Treated Pneumonia

Gram-negative bacteria are the likely causative agents of most pneumonia infections and physicians treat most of these patients with levofloxacin, ceftriaxone, and azithromycin. From 2010-2015, drug resistant organisms caused a surprising 20% of bacterial pneumonia infections.

This report provides quantitative, objective data using real-world patient encounters and reflects real physician decisions and encounter characteristics (e.g. patient response to therapy and outcomes) in key areas, such as antibiotic resistant pathogens and antimicrobial stewardship.

Table of Contents 

  1. Patient Flow
  2. Executive Summary
  3. Incidence and Impact of Disease
    • Incidence
    • Length of Stay
    • Total Cost
  4. Patient Demographics
    • Age
    • Insurance type
    • Gender
    • Region
    • Mortality
    • Comorbid Conditions
  5. Patient Segmentation by Diagnostic Testing
    • Causative Etiologic Agent
  6. Length of Stay and Cost by Patient Segment
    • Age at Admission
    • APACHE II Score
    • First Care Setting
  7. Patient Flow through the Hospital
    • Admission Site
    • Lab Testing
    • Lab TAT
    • Results
    • Etiology
    • Empiric Therapy
    • Change in treatment
  8. Drug Share for Key Therapeutics
    • Most Common
    • LOS
    • APACHE Score
    • Treatment Duration
    • Product Dashboards
      • Market Share
      • Demographics
  9. Hospitalization
  10. Outcomes of Treatment
    • Antibiotic Usage
    • Mortality
    • Cost per Patient
  11. Drug Resistant Pneumonia
    • Current Trends
    • Costs
    • Comorbidity
    • LOS
    • Mortality
  12. Database Overview
  13. Methodology

Instructions for Purchase:

1. Click the checkout button or go to your cart in the menu to check out

2.  Fill out in the information on the checkout page and click “Purchase”

3.  You will be redirected to a PayPal (you can check out with PayPal or any credit card by clicking “Pay with debit or credit card”)

4. Complete your purchase and click “Return to Merchant”

5. Your report will be available for download on the purchase confirmation screen and you will be e-mailed a copy of your report

Purchase